Failure reasons of drugs targeting EGFR in GBM, compared to therapeutic efficacy observed in other tumors, may depend on several reasons, including GBM tissue heterogeneity and the restricted access of TKIs due to the BBB (31). Here, EGFR is linked to glioblastoma.